AI-guided decision support for managing pancreatic conditions
Official title: A Multicenter Clinical Study on AI-Powered Precision Decision-Making Management for Pancreatic Diseases Using Contrast-Enhanced CT
Run by Changhai Hospital · NCT07439757 · Data updated 2026-11-12
This project will test an AI tool that reads contrast-enhanced CT scans to help doctors decide whether people with suspected pancreatic disease need surgery, close monitoring, or routine follow-up.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | Changhai Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | March 1, 2026 |
| Main results expected | October 31, 2029 |
| Study ends | October 31, 2029 |
| Registry record updated | February 27, 2026 |
| Trial ID | NCT07439757 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with clinically suspected pancreatic disease who are scheduled for contrast-enhanced CT and can provide informed consent.
✕Probably not a fit
Patients with prior pancreatic surgery, contraindications to contrast-enhanced CT, poor-quality images, or other conditions that prevent reliable CT interpretation are unlikely to benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter observational study using an AI deep-learning system to classify contrast-enhanced CT images of patients with suspected pancreatic disease into three care pathways: Intervention, Intensive Surveillance, or Routine Surveillance. The AI classifications are compared with clinicians' decisions and with pathological diagnosis or long-term follow-up as the gold standard. Primary outcomes include AI classification accuracy, the risk of missed malignant lesions, rates of unnecessary surgery, and agreement with standard clinical decision-making. The study also records safety and the real-world clinical utility of following AI-recommended management.
Why it matters
Potential benefit: If successful, the AI could help doctors detect malignant pancreatic lesions earlier and reduce unnecessary surgeries by improving decision consistency.
How similar studies have gone: Previous retrospective and single-center studies of AI for pancreatic imaging have shown promise for lesion detection and risk stratification, but prospective multicenter validation remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinically suspected pancreatic disease. * Scheduled to undergo contrast-enhanced CT. * Signed informed consent form indicating agreement to participate. Exclusion Criteria: * History of pancreatic surgery. * Contraindications to contrast-enhanced CT, including known hypersensitivity to iodinated contrast media or severe renal/hepatic dysfunction. * Suboptimal image quality affecting diagnosis. * Concurrent participation in another interventional clinical trial. * Unsuitability for participation as determined by the investigator, including but not limited to: pregnancy or lactation, severe psychiatric disorders or cognitive impairment, significant comorbidities that may interfere with study results or patient safety.
Where it's running
-
Changhai Hospital
Shanghai, China Recruiting
Study contacts
- Study coordinator: Beilei Wang, Doctor
- Email: lilly_wang@126.com
- Phone: +86 13774238083
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Blood protein biomarkers to help diagnose pancreatic cancer in adults
This study tests whether blood protein biomarkers can help detect pancreatic ductal adenocarcinoma and tell it apart from chronic pancreatitis and mucinous pancreatic lesions, and whether combining markers with CA 19-9 improves accuracy.
-
Odesa Criteria 2026: tests for autoimmune pancreatitis diagnosis
This study checks if the OC26 scoring system can accurately diagnose autoimmune pancreatitis in adults who may have AIP or related pancreatic diseases.
-
Using AI for early screening of pancreatic cancer
This study is testing if using artificial intelligence can help find pancreatic cancer earlier in people who are at high risk, like those with new diabetes or family history of the disease.
-
Collecting medical information and tissue samples from patients with pancreatic disorders
This study is collecting medical information and samples from people with pancreatic cancer or other pancreatic disorders to help find better ways to detect and treat these diseases.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery
This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.